Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect…

Overview of attention for article published in CNS Drugs, August 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

policy: 2 policy sources

Citations

dimensions_citation: 31 Dimensions

Readers on

mendeley: 73 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 5 policy documents that reference this research output.

Attention deficit hyperactivity disorder: diagnosis and management : D: Pharmacological safety

Cited by National Institute for Health and Care Excellence on 11 Sep 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Attention deficit hyperactivity disorder: diagnosis and management : C: Pharmacological efficacy and sequencing

Cited by National Institute for Health and Care Excellence on 09 Mar 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Attention deficit hyperactivity disorder: diagnosis and management: Evidence review

Cited by National Institute for Health and Care Excellence on 01 Sep 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Attention deficit hyperactivity disorder: diagnosis and management: Evidence review

Cited by National Institute for Health and Care Excellence on 01 Sep 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Guanfacine hydrochloride

Cited by Canadian Agency for Drugs and Technologies in Health on 17 Dec 2015

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.